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ABSTRACT
This study aimed to determine the effect of highly active anti-retroviral therapy (HAART) and hepatitis
C virus (HCV) co-infection on peripheral levels of interleukin (IL)-2, IL-10, IL-12 (p70), IL-18 and soluble
tumour necrosis factor receptor type II (sTNFRII). Serum levels were monitored for a 1-year period in 25
patients infected with human immunodeficiency virus-1 (HIV-1) who were naive for HAART at the
initiation of the study, and in four HIV-1-infected long-term non-progressors. Serum levels of both IL-18
and sTNFRII at baseline were significantly higher in HIV-1-infected patients than in controls. Baseline
levels of IL-18 and sTNFRII were not significantly different in long-term non-progressors compared with
the other patients. HCV co-infected patients had significantly higher levels of IL-18 and sTNFRII at each
time-point compared with patients who were not co-infected with HCV. Irrespective of HCV status,
response to HAART resulted in a significant decrease in the levels of both IL-18 and sTNFRII,
particularly among patients who achieved HIV viral suppression, but the net decrease observed at the
end of follow-up was lower in patients co-infected with HCV. No information was obtained from IL-2,
IL-10 and IL-12 (p70) measurements. The data suggest that analysis of serum levels of IL-18 and sTNFRII
may be a valuable tool for evaluating the response to HAART, and perhaps for assessing the degree of
immune restoration achieved by HAART responders. The results also highlight the relevance of
considering the HCV infection status of HIV-1-infected patients in order to avoid misinterpretation of
IL-18 and sTNFRII measurements.
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INTRODUCTION
The implementation of highly active anti-retrovi-
ral therapy (HAART) has dramatically reduced
the mortality and morbidity associated with
chronic human immunodeficiency virus (HIV)
infection [1]. Several virological and immunolo-
gical markers have been assessed for their value
in predicting both the response to HAART and
the risk of progression to AIDS. Of these markers,
enumeration of peripheral CD4+ T-cells and,
particularly, measurement of plasma HIV load
have been shown to be the most reliable [2];
however, the systematic determination of the
latter is hindered by its high cost and complexity.
Analyses of either serum or plasma levels of
cytokines, chemokines and surrogate markers of
immune activation have been performed by a
number of groups, with the aim of identifying
biological markers capable of predicting either
response or failure to HAART, and of assessing
the degree of immune restoration achieved by
patients who respond to therapy [3]. The latter
would be of particular interest in cases of so-
called immunovirological discordant responses.
A number of commercial ELISAs, which are sim-
ple and low-cost procedures that are applicable
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easily in low-grade socioeconomic settings, are
available for this purpose. These studies have
yielded conflicting data, probably because of
inconsistent study designs and patient inclusion
criteria, the lack of standardisation of most pro-
cedures [4], and perhaps the presence or absence
of certain factors, e.g., some metabolic diseases
and hepatitis C virus (HCV) infection, which have
been shown to alter peripheral levels of a number
of the markers mentioned above [5,6]. In the
present study, the effects of HAART and HCV co-
infection on the serum levels of several immuno-
regulatory and pro-inflammatory cytokines were
investigated in a cohort of HIV-1 infected patients
who were naive for HAART on entry to the study.
MATERIALS AND METHODS
Patients
A longitudinal study was conducted with 29 patients (12
males). The mean patient age at inclusion was 34.4 years (range
26–51 years). The clinical, demographical, immunological and
virological data for these patients at baseline are summarised in
Table 1. The clinical stages of patients were: stage A (23
patients); stage B (one patient); and stage C (five patients).
Twenty-three patients had no history of anti-retroviral treat-
ment on entry. The remaining six patients had received (but not
during the previous 3 months) either monotherapy or dual
therapies comprising nucleoside analogues. Twenty-five of the
29 patients initiated HAART at the beginning of the study.
HAART combinations included at least one HIV protease
inhibitor and one or two reverse transcriptase inhibitors. Four
patients, considered to be long-term non-progressors (LTNPs;
defined as being asymptomatic, untreated and infected for
> 10 years, with CD4+ cell counts > 500 cells ⁄mm3 andHIV viral
loads < 10 000 copies ⁄mL), remained untreated during follow-
up. Nineteen of the 29 patients were chronic HCV carriers and
were viraemic at entry (Amplicor HCV v.2.0; Roche Molecular
Systems, Basel, Switzerland). None of these patients was
receiving HCV-specific antiviral treatment at time of entry or
received HCV-specific antiviral treatment during the study.
Clinical and analytical controls were performed at baseline and
at 6 and 12 months after initiation of the study. These
evaluations included analysis of peripheral CD4+ T-cell counts,
measurement of HIV viral load, and determination of serum
levels of the following cytokines: interleukin (IL)-2, IL-10, IL-12
(p70), IL-18 and the cytokine receptor soluble tumour necrosis
factor receptor type II (sTNFRII).
Virological responders to HAART were defined as
patients who demonstrated a reduction in plasma viral load
of > 1.5 log from the baseline value, or maintained an
undetectable viral load (< 50 copies ⁄mL) throughout the
study. Immunological responders to HAART were those
who showed an increase in CD4+ T-cell count of ‡ 10% at
the end of the study compared with the pre-treatment value.
None of the patients had any clinical or analytical evidence
of metabolic disease during the study period, or a clinical
acute episode compatible with microbial infection within
1 month of sampling. Sera from 15 healthy immunocompe-
tent individuals (seven males, mean age 32.7 years, range
22–47 years) were used as controls.
Plasma HIV viral load
HIV copy number in plasma was determined by PCR with the
Amplicor HIV-1 monitor kit (Roche Molecular Systems), with
a lower limit of detection of 50 RNA copies ⁄mL.
T-cell phenotyping
Lymphocyte subsets were enumerated in freshly obtained
whole blood using the following labelled murine monoclonal
antibodies: CD4+ PerCP, CD45 RO+ phycoerythrin (PE) and
CD45 RA ± FITC (Becton Dickinson, Sparks, MD, USA), in
conjunction with a FACS Scalibur Cytometer (Becton Dickin-
son).
Serum cytokine analysis
Serum IL-2, IL-10 IL-12 (p70), IL-18 and sTNFRII levels were
quantified by ELISAs purchased from Biosource Europe
(Nivelles, Belgium). Serum samples had been stored previ-
ously at )70C. All samples belonging to a particular patient
were assayed in a single run. Concentrations of cytokines in
serum samples were determined by comparing the ODs of
the samples with the standard curves. Sensitivities of the
assays were as follows: IL-2, 0.1 pg ⁄mL; IL-10, 1 pg ⁄mL;
IL-12 (p70), 0.5 pg ⁄mL; IL-18, 12.5 pg ⁄mL; and sTNFRII,
0.1 ng ⁄mL.
Table 1. Demographical, clinical, immunological and
virological data at entry for patients infected with human
immunodeficiency virus-1 (HIV-1) who were included in
the study
Patient Gender Age Risk-factor CDC group HCV CD4+T HIV load Therapy
1 F 26 Hetero A – 370 7800 Naive
2 F 29 Hetero A – 700 143 000 Naive
3 F 32 Hetero A – 696 20 800 Dual
4 F 36 Hetero C (PT) – 795 5029 Dual
5 F 42 Hetero A – 272 68 000 Naive
6 M 51 Hetero C (HE) – 84 120 000 Naive
7 M 35 IDU C (WS) – 150 185 000 Mono
8 M 29 Hetero C (PP) – 4 330 000 Naive
9 M 34 Hetero A – 300 14 000 Naive
10 F 28 Hetero C (PT) – 20 100 000 Naive
11 M 38 IDU A + 580 9321 Naive
12 M 34 IDU A + 570 26 000 Naive
13 F 38 Hetero A + 336 43 200 Naive
14 F 32 IDU A + 180 670 000 Dual
15 F 28 IDU B + 900 5000 Naive
16 M 45 IDU A + 430 53 000 Dual
17 F 39 IDU A + 575 34 342 Dual
18 F 37 IDU A + 28 290 000 Naive
19 F 36 IDU A + 580 6000 Naive
20 F 26 Hetero A + 455 2200 Naive
21 F 43 Hetero A + 272 68 000 Naive
22 M 34 IDU A + 250 100 000 Naive
23 M 30 IDU A + 210 38 000 Naive
24 M 32 IDU A + 10 720 000 Naive
25 M 34 IDU A + 40 100 000 Naive
26 F 28 IDU A (LTNP) + 700 8000 Naive
27 F 27 IDU A (LTNP) + 1000 907 Naive
28 F 47 IDU A (LTNP) + 800 200 Naive
29 M 30 IDU A (LTNP) + 630 200 Naive
HE, HIV-induced encephalopathy; HCV, hepatitis C virus infection; IDU, intra-
venous drug user; LTNP, long-term non-progressor; PP, Pneumocystis pneumonia;
PT, pulmonary tuberculosis; WS, wasting syndrome.
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Statistical analysis
Measured levels of cytokines are expressed as means and
standard errors of the mean (± SE). Statistical analysis was
performed with the SPSS statistical package v. 9.0 (SPSS Inc.,
Chicago, IL, USA). Cytokine levels measured at each time-
point were compared on the basis of paired t-tests (using the
Mann–Whitney non-parametric test when indicated). Two-
sidedpvalues< 0.05were consideredsignificant. For correlation
analyses, the Spearman non-parametric test was performed.
RESULTS
All patients treatedwithHAART (n = 25) respond-
ed both immunologically and virologically to
therapy. The remaining four patients, categorised
as LTNPs, remained untreated throughout the
study and maintained stable levels of CD4+
T-cells and low plasma viral loads. Response to
HAART was manifest at 6 months after initiation
of therapy in all cases. Significant increases (p
0.01) in median peripheral levels of CD4+ T-cells
were achieved 12 months after initiating HAART
(with a mean increase of 512 cells ⁄mm3). Overall,
the decrease in median plasma viral load was
statistically significant after treatment for
6 months (p 0.01). Nineteen of 29 patients
achieved complete viral suppression (< 50 RNA
copies ⁄mL) during the study period.
The serum levels of cytokines were determined
in 83 samples obtained sequentially from 29
patients (LNTPs were analysed only at baseline
and 6 months thereafter), and in single serum
samples drawn from 15 HIV-seronegative healthy
controls matched for age and gender. IL-10 and
IL-12 (p70) were not detected in samples from
HIV-1 infected patients. In contrast, IL-2, IL-18
and sTNFRII were detected consistently in serum
samples from all individuals.
For IL-2, serum levels measured in HIV-1-
infected individuals showed no significant vari-
ation during the study period, irrespective of
whether the patients were co-infected with HCV.
In addition, no correlation was found between
CD4+ T-cell levels and serum IL-2 levels (p 0.5).
Overall, baseline levels of IL-18 (652 ±
270 pg ⁄mL) and sTNFRII (10.9 ± 4 pg ⁄mL) in
HIV-1-infected patients were significantly higher
than those in healthy controls (125 ± 56 pg ⁄mL
and 2.1 ± 1 ng ⁄mL; p 0.02 and p 0.03, respect-
ively). Likewise, as shown in Fig. 1, baseline levels
of IL-18 and sTNFRII were significantly higher in
HCV co-infected individuals (731 ± 276 pg ⁄mL
and 12.3 ± 4 ng ⁄mL) than in those who were not
co-infected (508 ± 276 pg ⁄mL and 8.4 ± 4 ng ⁄mL;
p 0.021 and p 0.012, respectively). These two
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Fig. 1. Serum cytokine levels of IL-18 and s-TNFRII in patients infected with human immunodeficiency virus-1 (HIV-1)
and co-infected and non-co-infected with hepatitis C virus (HCV) at baseline and at 6 and 12 months after initiation of
highly active anti-retroviral therapy (HAART). In each panel, data in the left row belong to HCV-negative HIV-1-infected
individuals, and data in the right row belong to HIV-1 infected individuals co-infected with HCV.
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groups of patients did not differ significantly (p
0.5) in terms of baseline CD4+ T-cell counts and
plasma HIV load.
Table 2 summarises the data relating to serum
levels of both cytokines over time in patients
receiving HAART (n = 25). Baseline levels of IL-
18 and sTNFRII decreased significantly after
6 months of HAART (p 0.013 and p 0.013,
respectively). However, no significant differences
were found between cytokine levels measured at
6 and 12 months post-HAART (p 0.35 and p 0.27,
respectively). A net decrease found between
baseline levels and those at the end of follow-up
proved statistically significant for IL-18 (p 0.03),
but not for sTNFRII (p 0.09). Maximum decrease
in cytokine levels during follow-up was observed
in patients who achieved complete viral suppres-
sion, but normal levels (i.e., those measured in
controls) of both cytokines were not achieved in
any patient by the end of follow-up.
Response to HAART resulted in a significant
decrease in IL-18 and sTNFRII serum levels (Fig.
1), regardless of whether patients were co-infect-
ed with HCV, although the decrease tended to be
of a greater magnitude in non-HCV co-infected
individuals at the end of follow-up (Table 2).
Values measured at each time-point were signifi-
cantly higher in HCV co-infected patients than in
non-co-infected individuals (except for sTNFRII
at 6 months). Interestingly, serum levels of both
cytokines at 6 months after initiation of HAART
in HCV co-infected patients were comparable
with baseline levels in patients not infected with
HCV.
Baseline levels of IL-18 and sTNFRII were
slightly lower in non-progressors (612 ± 198 and
10.1 ± 2, respectively) than in the other group of
patients (658 ± 270 and 11.1 ± 2, respectively),
but this difference did not reach statistical signi-
ficance (p 0.78 and p 0.72, respectively). In the
former patients, the levels of both cytokines
remained relatively constant after a further
6 months (662 ± 257 and 13.2 ± 2, respectively).
Overall, serum levels of IL-18 did not correlate
significantly with either CD4+ T-cell counts (p
0.29) or plasma HIV load (p 0.5). Indeed, although
mean basal levels of both cytokines were higher in
patients with lower counts (< 350 ⁄mm3) than in
those with higher counts (> 350 ⁄mm3) (IL-18,
703.15 pg ⁄mL vs. 608.13 pg ⁄mL; sTNFRII,
11.7 ng ⁄mL vs. 8.99 ng ⁄mL), the differences
failed to reach statistical significance. In contrast,
serum levels of sTNFRII tended to correlate with
both CD4+ T-cell counts (r = 0.317) and HIV-1
viral load (r = ) 0.36), although statistical signi-
ficance was again not reached (p 0.06 and p 0.055,
respectively).
DISCUSSION
This longitudinal study measured serum levels of
several immunoregulatory cytokines (IL-2 and IL-
10) and pro-inflammatory molecules (IL-12 (p70),
IL-18 and sTNFRII) in a population of HAART-
naive HIV-1-infected individuals in different dis-
ease stages and in several HIV-1-infected LTNPs.
Informative data could only be obtained from
measurements of IL-18 and sTNFRII, as these
molecules were detected consistently in serum
samples of all individuals. In contrast, IL-10 and
IL-12 (p70) were not detected at any level in
samples from HIV-1-infected patients, and IL-2
levels were found not to vary substantially during
follow-up. Thus, analysis focused on IL-18 and
sTNFRII.
IL-18 is a pleiotropic cytokine produced by
activated macrophages and dendritic cells, as well
as by certain epidermal cells [7,8], and plays an
important role in promoting TH1 responses [9].
Recent data suggest a relevant role for IL-18 in the
pathogenesis of HIV infection, since by virtue of
its pro-inflammatory effect, this cytokine might
enhance HIV replication and thus accelerate pro-
gression of the disease, particularly in late stages
of infection [10,11]. In contrast, sTNFRII is a stable
surrogate marker for TNF-a levels and activity
[12]. Circulating levels of sTNFRII in blood might
thus reflect the degree of immune activation.
Elevated levels of sTNFRII have been reported in
HIV-1-infected patients, particularly in those with
an advanced stage of the disease [12–14].
Table 2. Serum levels of IL-18 and sTNFRII in patients
infected with human immunodeficiency virus-1 (HIV-1)
and treated with highly active anti-retroviral therapy
(HAART) who were either co-infected or not co-infected
with hepatitis C virus (HCV)
Cytokine and time of sampling HCV(+) HCV(–) p
IL-18 pg ⁄mL (SE)
Baseline 766(269) 508(198) 0.021
6 months 575(128) 419(172) 0.012
12 months 697(169) 347(136) 0.001
sTNFRII ng ⁄mL (SE)
Baseline 12.8(4) 8.4(4) 0.011
6 months 7.9(4) 7.4(2) 0.342
12 months 11.1(5) 6.0(2) 0.002
sTNFRII, soluble tumour necrosis factor receptor type II.
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The present data indicate that serum levels of
both IL-18 and sTNFRII are significantly elevated
in HAART-naive HIV-1-infected individuals in
comparison with healthy controls; these data are
in agreement with those of previous studies [11–
19] in which patients with AIDS were found to
display higher serum levels of these cytokines
than individuals in earlier stages of HIV disease.
This led to the proposal that peripheral levels of
these cytokines could be used as surrogate mark-
ers for disease progression. This could not be
confirmed in the present study, given the small
number of patients in a late stage of disease;
however, the fact that baseline levels of IL-18 and
sTNFRII were significantly higher in patients with
lower CD4+ T-cell counts (< 350 ⁄mm3) than in
those with higher counts (> 350 ⁄mm3), together
with the observation of a trend towards a positive
correlation between plasma HIV-1 viral load and
serum levels of cytokines (particularly sTNFRII),
seems to support the above hypothesis.
Secondly, response to HAART was associated
significantly with a decrease in serum levels of IL-
18 and sTNFRII that was noticeable at 6 months
after the initiation of therapy. This effect was
particularly manifest among those patients who
achieved complete suppression of HIV replica-
tion. These data support previous observations
[11,15–19] and indicate that measurement of
peripheral levels of both cytokines may be of
clinical utility for monitoring the response to
HAART. Normal levels (i.e., those measured in
controls) were not reached at the end of follow-up
in any patient, thus indicating that the immuno-
virological response to HAART is not associated
necessarily with full normalisation of cellular
immunity. Therefore, monitoring of serum levels
of both cytokines may provide valuable informa-
tion concerning the degree of immune restoration
experienced by these patients. This might be of
particular interest in the case of patients display-
ing immunovirological discordant responses.
Thirdly, the most novel finding of the present
work was the demonstration of the effect of HCV
co-infection on peripheral levels of both cytok-
ines, both before and after initiation of HAART.
Higher levels of serum sTNFRII have been repor-
ted in HCV-infected cirrhotic patients than in
non-cirrhotic individuals [20]. The presence of
high levels of circulating IL-18 in patients with
chronic HCV infection, when compared with
healthy controls, and the role of this cytokine in
mediating the hepatic necroinflammatory re-
sponse in these patients, have been reported
previously [6,21–23]. The present study found
that HCV co-infected patients, who were viraemic
at entry and who were not receiving specific anti-
HCV treatment, had significantly higher serum
levels of both IL-18 and sTNFRII at each time-
point analysed in comparison with those who
were not co-infected. In addition, the net decrease
in circulating levels of both cytokines at the end of
follow-up, as a result of immunovirological
response to HAART, was significantly lower in
HCV co-infected patients than in non-co-infected
patients. Indeed, levels measured after 6 months
of HAART in the former patients were compar-
able with those measured at baseline in the latter
patients.
Overall, these data suggest that HCV and
HIV infection might act synergically in up-
regulating synthesis of these pro-inflammatory
cytokines, which emphasises the need to consi-
der the HCV status of patients in order to
interpret the circulating levels of both molecules
accurately and to infer the correct level of
response to HAART or the degree of immune
restoration achieved following therapy. Confir-
mation of this suggestion requires the analysis
of a larger population. In addition, it would be
of great interest to determine whether serum
levels of IL-18 and sTNFRII correlate with
peripheral HCV viral loads or HCV genotypes
in HCV co-infected patients.
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